The director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University discussed the advancements in epilepsy research, especially for drug-resistant epilepsy, to be presented at AES 2023. [WATCH TIME: 4 minutes]
The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.
The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.
The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to try and find the right medications for their patients as early as possible.
The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to actively look for new medications for patients to try.
The director of the Mid-Atlantic Epilepsy and Sleep Center also noted how serious adverse effects from treatment can be detrimental to patients’ lives.
The director of the Mid-Atlantic Epilepsy and Sleep Center also urged physicians to not give up on the search for effective AEDs for their patients.
The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, described the challenges he’s faced when having to discuss a change in treatment strategies with his patients.
The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, explained when and how prescription management changed amid the COVID-19 pandemic.
The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, shared his thoughts on how technology has affected patient care and the patient-physician dynamic during the COVID-19 pandemic.
The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, discussed whether certain epilepsy populations were affected greater by the COVID-19 pandemic.
Published: October 10th 2020 | Updated:
